Sign In

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.



The company announced today that it has raised just over £350k from a consortium of investors from the London Business Angels (LBA) network and from the management team. The money will be used to support multi-centre clinical trials of its new hand-held Multi-Beam Optical Coherence Tomography (OCT) imaging probe, and also aid international commercial growth.

“We received tremendous customer interest in our new ‘VivoSight’ Multi-Beam OCT probe, when we demonstrated the working prototype at the BiOS09 show (San Jose) in January”, said Michelson’s CEO, Jon Holmes, “and sales of our EX1301 OCT Microscope have accelerated in the last two quarters”. He added “We plan to launch VivoSight with UK clinical approvals in May/June this year, and I believe that we will post triple-digit sales growth in 2009”.

MDL received early stage funding of £600k in October 2007, and a further £600k in July 2008, in rounds led by London Seed Capital Ltd with Catapult Venture Managers Ltd and the LBA. It has offices in Kent and the West Midlands and was founded in 2006 by Jon Holmes and four other ex-employees of Sira, the photonics instrumentation company.

MDL’s Chairman, John Knowles, commented on the company’s fundraising strategy: “The management team has continued to achieve key milestones on time and on budget, and this has enabled a successful fundraising at a time when money is scarce and without loss of value for existing shareholders. We are now well placed to raise a much larger sum, timed to coincide with the economic recovery and results from clinical trials.”

The ‘VivoSight’ Multi-Beam OCT imaging technology has better resolution than competing OCT systems. This could revolutionize cancer diagnosis and treatment by potentially enabling clinicians to see, in real- time, (and at far higher resolution than is possible with current ultrasound, MRI or CT imaging), the location and extent of a tumour, for a range of cancer types. It is anticipated that the equipment will enable faster, more accurate cancer surgery, with major benefits for both the patient and clinician – removing the slow, painstaking process of taking multiple samples of tissue for analysis. Primary applications are expected to be skin and oral cancer, but many other cancers will be accessible via future variants of the probe, and there are also many other clinical and non-clinical applications for this powerful new imaging technology. The company has already conducted trials on excised human cancer tissue in the UK, Germany and the US, and will commence in vivo trials during 2009.

- ends –

Editor’s Notes:

Michelson Diagnostics Ltd

Michelson Diagnostics Ltd is the UK’s leading independent manufacturer and developer of Optical Coherence Tomography medical imaging equipment. Founded in 2006, it is based in SE London, UK.
For further information, contact Jon Holmes of Michelson Diagnostics Ltd at or call +44 (0) 208 308 1695

The Michelson Diagnostics logo is a trademark of Michelson Diagnostics Ltd and is registered in the UK & the US.
The VivoSight name is a trademark of Michelson Diagnostics Ltd and is registered in the UK.

Publisher Contact Information:

Michelson Diagnostics
0 208 308 1695

Company profile of Michelson Diagnostics
Past press releases of Michelson Diagnostics.


Tech investments
From our Online Data Service
VC-backed companies
From our Radar

Recent Deals

Nov 25€24.0MInternet commerce
Nov 8N/AOther Computers & Electronics
Nov 5€2.1MAudio/Video
Nov 5€5.2MOther Computers & Electronics
Nov 5€0.4MInternet services
Nov 5€1.3MSecurity
Nov 5€1.5MAudio/Video

For information on Europe's most extensive database on technology funding click here!


Press Releases

Sep 30
tetavi raises $6 million to help more companies bring 3d holograms ...

May 28
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
nethone raised over $1 million from innovation nest

Mar 31
the fit allocates chf 100'000 to comppair technologies

Jan 29
yumpingo raises $10m to transform guest experiences in restaurants

About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.